Use of aflatoxin adducts as intermediate endpoints to assess the efficacy of chemopreventive interventions in animals and man

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 402, Issue 1-2, 1998, Pages 165-172

  Kensler, Thomas W ^a,c   Groopman, John D ^a   Roebuck, Bill D ^b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Aflatoxin albumin adducts; Biomarkers; Chemoprevention; Chlorophyllin; Oltipraz

Indexed keywords

AFLATOXIN; CHLOROPHYLL; OLTIPRAZ;

CANCER; CANCER PREVENTION; CHEMICAL CARCINOGENESIS; CONFERENCE PAPER; DIAGNOSTIC VALUE; DRUG DNA INTERACTION; HUMAN; LIVER CANCER; LIVER CARCINOGENESIS; NONHUMAN; PRIORITY JOURNAL; RAT;

AFLATOXINS; ANIMALS; ANTICARCINOGENIC AGENTS; BIOLOGICAL MARKERS; DNA ADDUCTS; HUMANS; LIVER NEOPLASMS; PROSPECTIVE STUDIES;

EID: 0032543376     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-5107(97)00294-7     Document Type: Conference Paper

References (35)

1. [1] J.D. Groopman, T.W. Kensler, Molecular biomarkers for human chemical carcinogen exposures, Chem. Res. Toxicol. 6 (1993) 764-770.
2. [2] F.P. Perera, I.B. Weinstein, Molecular epidemiology and carcinogen-DNA adduct detection: new approaches to studies of human cancer causation, J. Chron. Dis. 35 (1982) 581-600.
3. [3] T.W. Kensler, J.D. Groopman, G.N. Wogan, 1996, Carcinogen-DNA and protein adduct biomarkers for cohort selection and as modifiable endpoints in chemoprevention trials, in: B.W. Stewart, D. McGregor, P. Kleihues (Eds.), Principles of Chemoprevention, IARC Scientific Publication No. 139, IARC, Lyon, pp. 237-248.
4. [4] D.L. Eaton, J.D. Groopman (Eds.), The Toxicology of Aflatoxins, Academic Press, San Diego, 1994.
5. [5] J.D. Groopman, L.G. Cain, T.W. Kensler, Aflatoxin exposure in human populations: measurements and relationships to cancer, CRC Crit. Rev. Toxicol. 19 (1988) 113-145.
6. [6] C.P. Wild, Y.Z. Jiang, G. Sabbioni, B. Chapot, R. Montesano, Evaluation of methods for quantitation of aflatoxin-albumin adducts and their application to human exposure assessment, Cancer Res. 50 (1990) 245-251.
7. 1-treated rats, Cancer Res. 41 (1981) 650-654.
8. 7-guanine and other aflatoxin metabolites by multiple monoclonal antibody affinity chromatography and HPLC, Cancer Res. 52 (1992) 67-274.
9. 7-guanine and serum aflatoxin-albumin adducts predicts chemoprotection by 1,2-dithiole-3-thione in rats, Carcinogenesis 13 (1992) 101-106.
10. 1 binding to plasma albumin and liver DNA upon chronic administration to rats, Carcinogenesis 7 (1986) 853-858.
11. 1 in vivo in rats, Carcinogenesis 8 (1987) 819-824.
12. [12] J.D. Groopman, J. Zhu, P.R. Donahue, A. Pikul, L.-S. Zhang, J.-S. Chen, G.N. Wogan, Molecular dosimetry of urinary aflatoxin DNA adducts in people living in Guangxi Autonomous Region People's Republic of China, Cancer Res. 52 (1992) 45-51.
13. 1, Carcinogenesis 9 (1988) 1323-1325.
14. 7-guanine in human urine obtained in The Gambia, West Africa, Cancer Epidemiol. Biomarkers Prev. 1 (1992) 221-228.
15. [15] C.P. Wild, G. Hudson, G. Sabbioni, G.N. Wogan, H. Whittle, R. Montesano, J.D. Groopman, Correlation of dietary intake of aflatoxin with the level of albumin bound aflatoxin in peripheral blood in The Gambia, West Africa, Cancer Epidemiol. Biomarkers Prev. 1 (1992) 229-234.
16. [16] T.C. Campbell, J. Chen, C. Liu, J. Li, B. Parpia, Non-association of aflatoxin with primary liver cancer in a cross-sectional ecological survey in the People's Republic of China, Cancer Res. 50 (1990) 882-6893.
17. [17] R.K. Ross, J.-M. Yuan, M.C. Yu, G.N. Wogan, G.-S. Qian, J.-T. Tu, J.D. Groopman, Y.-T. Gao, B.E. Henderson, Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma, Lancet 339 (1992) 943-946.
18. [18] G.-S. Qian, R.K. Ross, M.C. Yu, J.-M. Yuan, Y.-T. Gao, B.E. Henderson, G.N. Wogan, J.D. Groopman, A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China, Cancer Epidemiol. Biomarkers Prev. 3 (1994) 3-10.
19. [19] J.-S. Wang, G.-S. Qian, A. Zarba, X. He, Y.-R. Zhu, B.-C. Zhang, L. Jacobson, S.J. Gange, A. Muñoz, T.W. Kensler, J.D. Groopman, Temporal patterns of aflatoxin-albumin adducts in hepatitis B surface antigen positive and negative residents of Daxin, Qidong County, People's Republic of China, Cancer Epidemiol. Biomarkers Prev. 5 (1996) 253-261.
20. [20] S.-Y. Kuang, X. Fang, P.-X. Lu, Q.-N. Zhang, Y. Wu, J.-B. Wang, Y.-R. Zhu, J.D. Groopman, T.W. Kensler, G.-S. Qian, Aflatoxin-albumin adducts and risk for hepatocellular carcinoma in residents of Qidong, People's Republic of China, Proc. Am. Assoc. Cancer Res. 37 (1996) 252.
21. [21] L.-Y. Wang, M. Hatch, C.-J. Chen, B. Levin, S.-L. You, S.-N. Lu, M.-H. Wu, W.-P. Wu, L.-W. Wang, Q. Wang, G.-T. Huang, P.-M. Yang, H.-S. Lee, R.M. Santella, Aflatoxin exposure and the risk of hepatocellular carcinoma in Taiwan, Int. J. Cancer 67 (1996) 620-625.
22. [22] T.W. Kensler, E.F. Davis, M.G. Bolton, Strategies for chemoprotection against aflatoxin-induced liver cancer, in: D.L. Eaton, J.D. Groopman (Eds.), The Toxicology of Aflatoxins, Academic Press, San Diego, 1994, pp. 281-306.
23. 1-induced hepatocarcinogenesis in F344 rats by 5-(2-pyrazinyl)-4-methyl-1,2-dithiole-3-thione (oltipraz): predictive role for short-term molecular dosimetry, Cancer Res. 51 (1991) 5501-5506.
24. [24] P.A. Egner, S.J. Gange, P.M. Dolan, J.D. Groopman, A. Muñoz, T.W. Kensler, Levels of aflatoxin-albumin biomarkers in rat plasma are modulated by both long-term and transient interventions with oltipraz, Carcinogenesis 16 (1995) 1769-1773.
25. [25] M.G. Bolton, A. Muñoz, L.P. Jacobson, J.D. Groopman, Y.Y. Maxuitenko, B.D. Roebuck, T.W. Kensler, Transient intervention with oltipraz protects against aflatoxin-induced hepatic tumorigenesis, Cancer Res. 53 (1993) 3499-3504.
26. [26] T.P. Primiano, P.A. Egner, T.R. Sutter, G.J. Kelloff, B.D. Roebuck, T.W. Kensler, Intermittent dosing with oltipraz: relationship between chemoprevention of aflatoxin-induced tumorigenesis and induction of glutathione S-transferases, Cancer Res. 55 (1995) 4319-4324.
27. [27] N. Tachino, D. Guo, W.M. Dashwood, S. Yamane, R. Larsen, R. Dashwood, Mechanisms of the in vitro antimutagenic action of enzyme inhibition, molecular complex formation and degradation of the ultimate carcinogen, Mutat. Res. 308 (1994) 191-203.
28. 1: complex formation with the carcinogen, Chem. Res. Toxicol. 8 (1995) 506-514.
29. [29] R. Dashwood, S. Yamane, R. Larsen, Study of the forces stabilizing complexes between chlorophylls and heterocyclic amine mutagens, Environ. Mol. Mutagen. 27 (1996) 211-218.
30. 1 hepatocarcinogenesis in rainbow trout, Cancer Res. 55 (1995) 57-62.
31. [31] D. Guo, D. Horio, J. Grove, R. Dashwood, Inhibition by chlorophyllin of 2-amino-3-methylimidazo[4,5-f]quinoline-induced tumorigenesis in the male F344 rat, Cancer Lett. 95 (1995) 161-165.
32. [32] Y.-R., Zhu, J.-G. Chen, X.Y. Huang, Hepatocellular carcinoma in Qidong County, in: Z.Y. Tang (Ed.), Primary Liver Cancer, China Academic Publisher, Springer-Verlag, Beijing, pp. 204-222, 1989.
33. [33] S.Z. Yu, Primary prevention of hepatocellular carcinoma, J. Gastroenterol. Hepatol. 10 (1995) 674-682.
34. [34] M.S. Greenblatt, W.P. Bennett, M. Hollstein, C.C. Harris, Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis, Cancer Res. 54 (1994) 4855-4878.
35. [35] L.P. Jacobson, B.-C. Zhang, Y.-R. Zhu, J.-B. Wang, Y. Wu, Q.-N. Zhang, L.-Y. Yu, G.-S. Qian, S.-Y. Kuang, Y.-F. Li, X. Fang, A. Zarba, B. Chen, C. Enger, N.E. Davidson, M.B. Gorman, G.B. Gordon, H.J. Prochaska, P.A. Egner, J.D. Groopman, A. Muñoz, K.J. Helzlsouer, T.W. Kensler, Oltipraz chemoprevention trial in Qidong, People's Republic of China: study design and clinical outcomes, Cancer Epidemiol. Biomarkers Prev. 6 (1997) 257-265.